Skip to main content
NCBI home page
Integrative Medicine Research logoLink to Integrative Medicine Research
. 2019 Aug 31;8(4):240–246. doi: 10.1016/j.imr.2019.08.006

Herbal formula (Danggui Beimu Kushen Wan) for prostate disorders: a systematic review of classical literature

Hong Li a, Andrew Hung b, Angela Wei Hong Yang a,⁎
PMCID: PMC6804470  PMID: 31649859

Abstract

Background

Danggui Beimu Kushen Wan (DBKW) was initially known for difficult urination in pregnancy and has been widely used for prostate disorders in modern days. This study aimed to comprehensively investigate the implications of DBKW in traditional evidence.

Methods

The Encyclopedia of Traditional Chinese Medicine was searched to identify the ingredients, dosage, etiologies, pathogeneses, actions and indications related to DBKW documented in ancient books. Descriptive summary was provided to their characteristics.

Results

A total of 41 texts in 36 classic books were included. Two etiologies and 10 pathogeneses were investigated. All the identified formulas contain Angelicae Sinensis Radix, Fritillariae Thunbergii Bulbus and Sophorae Flavescentis Radix with the ratio of 1:1:1. The treatment dosage is three to 10 pills each time. The primary indication of DBKW is difficult urination with heat stagnation. Nine included texts specified that this formula could also be used for male.

Conclusion

Included classic literature has provided fundamental evidence for the management of difficult urination in female and male. Further studies should investigate its mechanisms of actions for difficult urination related conditions, such as prostate disorders.

Keywords: Herbal medicine, Prostate disorder, Urination, Classic literature, Text mining.

1. Introduction

The three most commonly seen prostate disorders, including prostatitis, benign prostatic hyperplasia and prostate cancer, affect about 26–50% of men in all ages worldwide.1, 2, 3 Within all prostate disorders, approximately 1.1 million patients were diagnosed with prostate cancer and around 307,000 deaths were recorded in 2012 globally.4 It is worth mentioning that patients with chronic prostatitis had an approximate 30% higher risk to develop prostate cancer than others in the future.5 Difficult urination, urogenital pain, frequent micturition, hematuria, urinary incontinence, acute urinary retention or sexual dysfunction may occur when prostate disorders are developed.6, 7, 8 Conventional management includes active surveillance and observation, surgery, radiation therapy, ablative treatments, hormone treatment, chemotherapy, immunotherapy, physiotherapy and psychotherapy.9, 10, 11 However, the therapeutic effects are unsatisfactory with inevitable adverse effects, such as fatigue, depression, postoperative pain, chemotherapy-induced or postoperative nausea and vomiting.9

Chinese herbal medicine, such as Danggui Beimu Kushen Wan (Chinese Angelica, Fritillaria and Flavescent Sophora Pill; DBKW), has been used for the management of urination-related disorders for thousands of years.12, 13 DBKW is also known as Guimu Kushen Wan (GKW; Chinese Angelica, Fritillaria and Flavescent Sophora Pill) or Kushen Wan (KW; Flavescent Sophora Pill) in Great Compendium of Chinese Medicinal Formulae.14 The original record of this formula can be traced back to Jin Gui Yao Lue (Synopsis of Prescriptions of the Golden Chamber; JGYL) written by ZHANG Zhong-jing (150–219 AD) about 1800 years ago.15 In modern clinical practice, DBKW has been consistently used for a number of diseases involving difficult urination, such as urinary retention in pregnancy,16 cystitis in pregnancy17 as well as prostate disorders (prostatitis,18 benign prostatic hyperplasia19 and prostate cancer20). Considering unsatisfactory current management of prostate disorders, DBKW may provide a new avenue for prostate disorders. Therefore, it is worth thoroughly investigating the traditional use of DBKW, especially for prostate-related symptoms, and comparing the differences between classic and contemporary applications. This study aimed to comprehensively investigate DBKW’s traditional evidence in classic literature that may provide modern clinical implications for drug discovery of prostate disorders.

2. Methods

A search of classic literature was conducted in Zhong Hua Yi Dian (Encyclopedia of Traditional Chinese Medicine; ZHYD), a CD-ROM containing 1156 ancient books.21 Keywords for searching in the CD-ROM included “Danggui Beimu Kushen Wan”, “Guimu Kushen Wan” and “Kushen Wan” in Chinese characters. All the retrieved texts were exported to an Excel file for screening.

The texts were included if they contain the formula name DBKW, GKW or KW, with or without ingredients, and published in China before 1950 since the year 1950 has been identified as the boundary timeline between classic and modern Chinese medicine history.22 The literature was excluded if the formula contains different ingredients from those described in JGYL even though it has the same formula name, or published in countries other than China, or published after 1950.

One reviewer (HL) screened the retrieved texts and extracted the following data to a predesigned Excel file: source of the classic book, author, published dynasty, formula name, ingredients, actions, indications and dosage. The second reviewer (AY) checked the data during the screening and extraction processes. Any discrepancies between two reviewers were resolved through discussion or the third party (AH). Descriptive summary was provided to the characteristics of extracted data. Dosage of DBKW in ancient units was converted to the international system of units (SI units).

3. Results

A total of 362 texts were identified from ZHYD and 41 of them containing 41 formulas in 36 books were included in this study. Details of identified 41 formulas are listed in Supplement 1. Fig. 1 illustrates the selection process of classic texts in this study.

Fig. 1.

Fig. 1

Open in a new tab

Selection process of classic texts to be included. DBKW: Danggui Beimu Kushen Wan, Chinese Angelica, Fritillaria and Flavescent Sophora Pill; GKW: Guimu Kushen Wan, Chinese Angelica, Fritillaria and Flavescent Sophora Pill; KW: Kushen Wan, Flavescent Sophora Pill.

3.1. Historical development of DBKW

Among 36 classic Chinese medicine (CM) books, 24 texts in 20 books documented the formula as DBKW, 13 texts in 12 books listed as GKW, and four texts in four books recorded as KW. Eleven books mentioned that this formula was cited from JGYL. All included books were published in seven dynasties between year 205 and 1949, including one text in the Eastern Han dynasty (25–220), one text in the Western Jin dynasty (265–316), two texts in the Southern Song dynasty (1127–1279), one text in the Yuan dynasty (1271–1368), nine texts in the Ming dynasty (1368–1644), 26 texts in the Qing dynasty (1644–1912) and one text in the Republic of China (1912–1949). Fig. 2 details the historical development of this formula.

Fig. 2.

Fig. 2

Open in a new tab

Historical development of Danggui Beimu Kushen Wan. Δ: Cited formula from Synopsis of Prescriptions of the Golden Chamber. The corresponding English book name referred to Supplement 1.

3.2. Etiologies and pathogeneses of DBKW

Twelve books published in the Qing dynasty described the etiologies and pathogeneses of this formula. There are two etiologies and ten pathogeneses mentioned in these books. Fig. 3 shows the primary syndromes treated by DBKW, including Qi stagnation and Blood deficiency due to pregnancy, followed by Qi deficiency due to pregnancy and external wind-cold invasion during pregnancy. With the development of the condition, it aggravates gradually and then may lead to diverse pathogeneses pathways, involving heat stagnation in Lower-Jiao, fetus heat and abdominal distention in pregnancy, and abnormal Bladder Qi-hua. Difficult urination finally occurs when insufficiency of the body fluids or stagnation in water passage is developed.

Fig. 3.

Fig. 3

Open in a new tab

Etiologies and pathogeneses of Danggui Beimu Kushen Wan. [a]Jin Gui Yu Han Jing Er Zhu; [b]Zhang Shi Yi Tong; [c]Tai Chan Xin Fa; [d]Jin Gui Yao Lue Xin Dian; [e]Jin Gui Yao lue Qian Zhu; [f]Jin Gui Fang Ge Kuo; [g]Nu Ke Yao Zhi; [h]Cheng Fang Qie Yong; [i]Chang Sha Yao Jie; [j]Jin Gui Xuan Jie; [k]Jin Gui Yao Lue Guang Zhu; [l]Gao Zhu Jin Gui Yao Lue. The corresponding English book name referred to Supplement 1.

3.3. Ingredients and dosage of DBKW

Among all the 41 identified formulas, Angelicae Sinensis Radix (Dang gui), Fritillariae Thunbergii Bulbus (Zhe bei mu) and Sophorae Flavescentis Radix (Ku shen) were the three basic ingredients of this formula. The only variation of this formula is that Talcum (Hua shi) is contained in 13 formulas (Supplement 1). The original record of this formula clearly indicated that Talcum was used for male patients only. Nine formulas specified that Talcum was only for male patients. Another four formulas included Talcum in its ingredients, however, no gender was specified in their indications. In terms of dosage, 23 formulas disclosed the dosage for each herb (ranging from half to four Liang) and administration of the formulas (ranging from three pills to 30 pills). Four books demonstrated the administration dosage of this formula without the dosage of each herb whilst two books presented the dosage of each herb, without providing administration dosage for each time. One book provided the herb name only, without a description of dosage. As the size of each pill was only documented as small beans, which is the alternative name of Vignae Semen (Chi xiao dou) in Chinese history.23 One author (HL) measured the weight of each Vignae Semen with a digital bench scale (Model: TSDS673, Wedderburn Scales Pty. Ltd.) to examine the administration dosage in the international system of units. The weight of each Vignae Semen is approximately 50 mg (Supplement 2).

As summarized in Table 1, the ratio of ingredients (following the herb sequence of Angelicae Sinensis Radix, Fritillariae Thunbergii Bulbus, Sophorae Flavescentis Radix and/or Talcum) were identified in three different suggested prescriptions: (1) 1:1:1 for everyone (14 books); (2) 8:8:8:1 for male and 1:1:1 for female (eight books); (3) 6:6:6:1 for everyone (five books). Furthermore, the administration dosage of this formula was recorded in three suggested prescriptions: (1) Three to 10 pills each time (23 books); (2) 20 pills each time (eight books); (3) 30 pills each time (one book).

Table 1.

Ingredients and dosage of Danggui Beimu Kushen Wan in historical development of Chinese medicine

Dynasty Per treatment dosage
 Weight equivalent to 1 liang (g) Patient gender (M/F) Weight of ingredient (Liang)
 Weight of ingredient per pill (mg)
 Ratio of ingredients Number of referencing books
Dang gui Bei mu Ku shen Hua shi Dang gui Bei mu Ku shen Hua shi
Eastern Han 0.15–0.5 g 3–10 pills 15.62 M 4 4 4 0.5 16 16 16 2 8:8:8:1 1 book[a]
F 4 4 4 / 16.67 16.67 16.67 / 1:1:1
Southern Song 1 g 20 pills 37.3 M & F 3 3 3 0.5 15.79 15.79 15.79 2.63 6:6:6:1 2 books [b]
Yuan 1 g 20 pills 37.3 M & F 3 3 3 0.5 15.79 15.79 15.79 2.63 6:6:6:1 1 book [c]
Ming 0.15–0.5 g 3–10 pills 37.3 M 4 4 4 0.5 16 16 16 2 8:8:8:1 4 books [d]
F 4 4 4 / 16.67 16.67 16.67 / 1:1:1
Ming 0.15–0.5 g 3–10 pills 37.3 M & F 4 4 4 / 16.67 16.67 16.67 / 1:1:1 2 books [e]
Ming 1.5 g 30 pills 37.3 M & F 3 3 3 0.5 15.79 15.79 15.79 2.63 6:6:6:1 1 book [f]
Qing 0.15–0.5 g 3–10 pills 37.3 M 3 3 3 0.5 15.79 15.79 15.79 2.63 6:6:6:1 1 book [g]
F 3 3 3 / 15.79 15.79 15.79 / 1:1:1
Qing 0.15–0.5 g 3–10 pills 37.3 M 4 4 4 0.5 16 16 16 2 8:8:8:1 3 books [h]
F 4 4 4 / 16.67 16.67 16.67 / 1:1:1
Qing 0.15–0.5 g 3–10 pills 37.3 M & F 4 4 4 / 16.67 16.67 16.67 / 1:1:1 12 books [i]
Open in a new tab

Note: Bei mu, Fritillariae Thunbergii Bulbus; Dang gui, Angelicae Sinensis Radix; F, Female; Hua Shi, Talcum; Ku shen, Sophorae Flavescentis Radix; M, Male.

[a] One book: Jin Gui Yao Lue; [b] Two books: San Yin Ji Bing Zheng Fang Lun, Fu Ren Da Quan Liang Fang; [c] One book: Shi Yi De Xiao Fang; [d] Four books: Yi Xue Gang Mu, Nu Ke Zheng Zhi Zhun Sheng, Zheng Zhi Zhun Sheng Lei Fang, Ji Yin Gang Mu; [e] Two books: Guang Si Ji Yao, Yin Chan Quan Shu; [f] One book: Pu Ji Fang; [g] One book: Jin Gui Qi Yue (Fu Ke); [h] Three books: Nu Ke Yao Zhi, Jin Gui Fang Ge Kuo, Jing Fang Li Shi; [i] 12 books: Jin Gui Yao Lue Guang Zhu, Jin Gui Yu Han Jing Er Zhu, Zhang Shi Yi Tong, Jin Gui Yao Lue Xin Dian, Tai Chan Xin Fa, Ding Zheng Zhong Jing Quan Shu Jin Gui Yao Lue Zhu, Chang Sha Yao Jie, Jin Gui Xuan Jie, Lan Tai Gui Fan, Jin Gui Yao Lue Qian Zhu, Gao Zhu Jin Gui Yao Lue, Ling Lin Ling Fang.

The corresponding English book name referred to Supplement 1.

3.4. Actions and indications of DBKW

All the 41 classic texts claimed the same indication of this formula: difficult urination during pregnancy with normal diet and appetite. Nine of them in three dynasties including Eastern Han dynasty (One text), Ming dynasty (four texts) and Qing dynasty (four texts) specified that this formula could also be used for male patients with difficult urination and normal appetite (Supplement 1). Four texts in three dynasties including Southern Song dynasty (two texts), Yuan dynasty (one text) and Ming dynasty (one text) did not mention whether DBKW could treat male urinary disorders although they included Talcum in their prescriptions. Only four texts detailed the possible target diseases of this formula. Specifically, Compendium of Medical Practice (Yi Xue Gang Mu) published in 1565 indicated that the target disease was Zhuan Bao, which is equivalent to urinary retention during pregnancy. Collections of Reproductive and Pediatric Disorders (Guang Si Ji Yao) written in 1573 and Essential Gynecology (Nu Ke Zhi Zhang) written in 1724 claimed that this formula could treat Zi Lin which is similar to urinary tract infections during pregnancy. Encyclopedia of Gynecological Disorders (Yin Chan Quan Shu), documented between 1549–1613, also recorded that this formula could be a treatment for Zhuan Bao as well as Zi Lin.

Although there was no general description for the actions of this formula in CM classic literature, the actions of individual herbs were recorded in 12 books in the Qing dynasty and they are summarized in Supplement 3.

4. Discussion

This study has thoroughly investigated and analyzed DBKW from various aspects, including its ingredients, dosages and indications. Classic literature clearly indicates DBKW can be used for both male and female when they suffer from difficult urination. Three or four ingredients of DBKW were consistently described in the classic texts. However, the use of Bei mu is the concern because there are three main species of Bei mu recorded in CM history, including Fritillariae Thunbergii Bulbus (Zhe bei mu), Fritillariae Cirrhosae Bulbus (Chuan bei mu) and Bulbus Bolbostemmatis Rhizoma (Tu bei mu) which ZHANG Zhong-jing did not specify in the original record.21 Among the 41 included texts, only Merits of Herbal Medicine (Ben Cao Zheng Yi; 1920, Republic of China) stated that Bei Mu in this formula should be Fritillariae Thunbergii Bulbus (Zhe bei mu) which is supported by modern research. Experimental studies have demonstrated that Fritillariae Thunbergii Bulbus (Zhe bei mu) could inhibit the abnormal immune response by relieving the inflammation and over-proliferation of fibroblasts of the prostate as well as reducing the serum level of nitric oxide in the mice model with immunological chronic prostatitis/chronic pelvic pain syndrome.24

4.1. Comparison between classic and contemporary implications

The detailed information of this study assists practitioners and researchers to develop a comprehensive understanding of this formula. DBKW was initially known for managing difficult urination in pregnancy. However, consistent evidence in the included classic literature has indicated that DBKW could also be used for male patients with difficult urination so that the indications of DBKW could be theoretically extended to urinary or reproductive disorders with the similar clinical manifestations in men, such as chronic prostatitis, benign prostatic hyperplasia, or prostate cancer.

A recently published review on clinical and experimental studies of DBKW has revealed that DBKW could be a promising formula with great potential for the management of chronic prostatitis.25 Specifically, four randomized controlled trials (RCTs) applied modified or basic DBKW to treat patients with chronic prostatitis.18, 26, 27, 28 Compared to antibiotic drugs, two RCT involving 170 and 156 patients respectively revealed that the modified DBKW significantly relieved difficult urination, perineal pain and tenderness of prostate after a four-week treatment.26, 27 However, the review did not synthesize the corresponding data since insufficient details provided in the original studies.25 Another RCT enrolling 100 patients reported that the pH level in the expressed prostatic secretions test was significantly reduced by the modified DBKW decoction after four weeks, compared to ofloxacin (mean difference (MD) −0.17, 95% confidence interval (CI) −0.33 to −0.01).28 The last study demonstrated adjunct effects of basic DBKW for patients with type III prostatitis on the reduction of NIH-Chronic Prostatitis Symptom Index in addition to terazosin hydrochloride after a six-week intervention (MD −3.08, 95% CI −5.50 to −0.66).18 In addition, the modified DBKW has also been reported to treat prostate cancer,20 prostatitis,29 and benign prostatic hyperplasia19, 30 in non-RCTs, case series and single cases. The outcomes demonstrated that DBKW could relieve difficult urination and eliminate or offset the adverse effects of chemotherapy. In terms of adverse events, only slight dizziness, fatigue and postural hypertension were complained by the participants in one RCT.18

Although DBKW has shown promising clinical effects in the recent studies, the recently published CM practice guidelines for prostate disorders did not include DBKW as the intervention.31 The treatment effects of this formula on male patients may be overlooked by practitioners and researchers since only nine included classic texts in five dynasties highlighted that this formula could be used for male as well. Nevertheless, we should not deny that DBKW has been consistently used for male along with the development of CM history, evidenced by the included classic texts. Considering the potential therapeutic effects and mild adverse events of this formula, practitioners and researchers should conduct more high quality RCTs to verify its clinical potentials on the prostate disorders in the future.

4.2. Experimental studies of DBKW

A recent review and some experimental studies of DBKW pointed out that DBKW may have multiple actions that could have effects on more than one pathway of prostate disorders at the same time.25, 32, 33, 34, 35, 36, 37, 38, 39 A number of animal studies investigated the mechanisms of actions of DBKW on rats or mice in the treatment of chronic bacterial prostatitis. Researchers believed that DBKW has shown anti-inflammatory, anti-fiber proliferation and bactericidal effects on the prostate gland, evidenced by relieving inflammatory cell infiltration, preventing the damage of epithelial cells during infection period, stimulating the recovery of prostate glandular tissue, restricting interstitial hyperplasia of prostate tissue,33 and decreasing the density of white blood cell while increasing the density of small particle of lecithin.37 DBKW also stimulated the immune system that reduced the positive expression of intercellular cell adhesion molecule-1,36 Interleukin (IL)-1β,32 IL-834 and tumor necrosis factor-α (TNF-α) mRNA.35 In addition, DBKW may have antagonistic effects on benign prostatic hyperplasia via decreasing the serum level of testosterone propionate and estradiol in the body,38 reducing the expression of proliferating cell nuclear antigen and B-cell lymphoma/leukemia-2 (Bcl-2) as well as increasing the expression of Bcl-2-associated X protein at the genetic level.39

Similar pharmacological effects were reported to the individual herbs contained in this formula.40, 41, 42 They could support the treatment effects of this formula. Recent laboratory studies reported that all Angelicae Sinensis Radix, Fritillariae Thunbergii Bulbus and Sophorae Flavescentis Radix have anti-inflammatory and immunoregulatory activities evidenced by decreasing the expression of TNF-α,43, 44, 45, 46, 47 IL-1β,48 IL-6,45, 46 IL-8,45 nuclear factor kappa light chain enhancer of activated B cells,49 as well as enhancing the expression of Interferon-γ.50 The therapeutic effects of DBKW on prostate disorders may be due to the multiple active compounds in DBKW, such as ferulic acid, oxymatrine, oxysophocarpine, matrine, sophocarpine, verticine and verticinone.25, 40, 41, 42, 51 However, the actual mechanisms of actions of DBKW for prostate disorders are unknown that should be comprehensively detected in the future. It could be an opportunity for researchers to discover new drugs for the management of prostate disorders, guided by ancient wisdom.52

4.3. Limitations of this study

A few limitations were inevitable in this study. Although this text-mining approach via ZHYD database searching has been considered as a systematical research method for classic literature, its thoroughness and comprehensiveness are subject to the availability of classic books included in the ZHYD.22 The recent review of modern literature on DBKW highlighted that the quality of its included RCTs is poor and more high quality clinical and experimental studies are recommended to verify its effects for the management of prostate disorders.25 In addition, a doubtful point has been noticed that the dosage recorded in the original text was too low for an adult after being converted to SI units, comparing to the dosage mentioned in the review.25 Thus, the treatment dosage in clinical practice should be further explored in future studies. Even though minor adverse effects were reported in modern clinical studies mentioned above, the safety and toxicity of DBKW should be further investigated.

In conclusion, classic literature has indicated that the primary indication of DBKW was difficult urination with heat stagnation and the treatment dosage of DBKW was three to 10 pills each time. Modern clinical and experimental studies mentioned above agreed that DBKW may have anti-cancer effect, anti-inflammatory effect, anti-proliferation effect and anti-bacterial effect for prostate disorders. Thus, DBKW seems a promising formula for the management of clinical conditions associated with difficult urination involving prostate disorders. However, the exact treatment dosage in modern SI units, adverse effects, toxicity and mechanisms of actions of DBKW for prostate disorders are still unclear. Further study should pay more attention to conduct high quality and well-designed RCTs, in vivo, in vitro and network pharmacological studies so that comprehensive investigation on the efficacy and safety of DBKW for the management of prostate disorders can be performed.

Author contributions

Conceptualization, H.L., A.H. and A.Y.; Methodology, H.L., A.H. and A.Y.; Software, H.L.; Validation, H.L., A.H. and A.Y.; Data Analysis, H.L. and A.Y.; Writing – Original Draft Preparation, H.L.; Writing – Review & Editing, H.L., A.H. and A.Y.; Supervision, A.H. and A.Y.

Conflict of interest

The authors declare no conflict of interest.

Funding

This research received no external funding.

Ethical statement

This study did not involve any human or animal experiment.

Data availability

The data used to support the findings of this study are included within the supplementary information files.

Footnotes

Details of individual herbs (ingredients) of Danggui Beimu Kushen Wan and measurement of Vignae Semen (Chi xiao dou) weight can be found, in the online version, at doi:https://doi.org/10.1016/j.imr.2019.08.006.

Supplementary material

The following are Supplementary data to this article:

mmc1.docx (34.1KB, docx)
mmc2.docx (376.3KB, docx)
mmc3.docx (27.5KB, docx)

References

  • 1.Krieger J.N., Lee S.W.H., Jeon J., Cheah P.Y., Liong M.L., Riley D.E. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31:85–90. doi: 10.1016/j.ijantimicag.2007.08.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pavone-Macaluso M. Chronic prostatitis syndrome: a common, but poorly understood condition. Part I. EAU-EBU Update Ser. 2007;5:1–15. [Google Scholar]
  • 3.Lee S., Chan E., Lai Y.K. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7:7984. doi: 10.1038/s41598-017-06628-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ferlay J., Soerjomataram I., Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. doi: 10.1002/ijc.29210. [DOI] [PubMed] [Google Scholar]
  • 5.Cheng I., Witte J.S., Jacobsen S.J. Prostatitis, sexually transmitted diseases, and prostate cancer: the California men’s health study. PLoS One. 2010;5:e8736. doi: 10.1371/journal.pone.0008736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Murphy A.B., Macejko A., Taylor A., Nadler R.B. Chronic prostatitis. Drugs. 2009;69:71–84. doi: 10.2165/00003495-200969010-00005. [DOI] [PubMed] [Google Scholar]
  • 7.Mottet N., Bellmunt J., Bolla M. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629. doi: 10.1016/j.eururo.2016.08.003. [DOI] [PubMed] [Google Scholar]
  • 8.Sarma A.V., Wei J.T. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367:248–257. doi: 10.1056/NEJMcp1106637. [DOI] [PubMed] [Google Scholar]
  • 9.James L.M., Emmanuel S.A., Andrew J.A. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505. doi: 10.6004/jnccn.2019.0023. [DOI] [PubMed] [Google Scholar]
  • 10.Rees J., Abrahams M., Doble A., Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116:509–525. doi: 10.1111/bju.13101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Andrology Australia. Prostate disease, BPH and prostatitis-diagnosis and management: clinical summary guide 7. NHMRC Website. https://www.clinicalguidelines.gov.au/portal/2498/prostate-disease-bph-and-prostatitis-diagnosis-and-management-clinical-summary-guide-7. Published 2015. Accessed June 20, 2019.
  • 12.Tong X.L., Dong L., Chen L., Zhen Z. Treatment of diabetes using traditional Chinese medicine: past, present and future. Am J Chin Med. 2012;40:877–886. doi: 10.1142/S0192415X12500656. [DOI] [PubMed] [Google Scholar]
  • 13.Seong K.M., Jang G., Kim D.W., Kim S., Song B.K. Hwanglyunhaedok pharmacopuncture versus saline pharmacopuncture on chronic nonbacterial prostatitis/chronic pelvic pain syndrome. J Acupunct Meridian Stud. 2017;10:245–251. doi: 10.1016/j.jams.2017.06.001. [DOI] [PubMed] [Google Scholar]
  • 14.Peng H. People’s Medical Publishing House; Beijing, China: 2000. Zhong Yi Fang Ji Da Ci Dian (Great Compendium of Chinese Medical Formulae) [Google Scholar]
  • 15.Zhang Z., Wiseman N., Wilms S. Paradigm Publications; Taos, New Mexico: 2013. Jin Gui Yao Lue: Essential Prescriptions of the Golden Cabinet. [Google Scholar]
  • 16.Wang S. Treatment of postpartum urinary retention by Danggui Beimu Kushen Wan combined with high dose of Huangqi: a report of 80 cases. Pub Med Forum M. 2009;13:254. [Google Scholar]
  • 17.Jiang C., He H. Cystitis treated by modified Danggui Beimu Kushen Wan: a report of 230 cases. Forum Tradit Chin Med. 1999;14:9. [Google Scholar]
  • 18.Zhang Q., Yang N., Chen Y. Randomised controlled clinical trials on Danggui Beimu Kushen decoction combined with α-blockers in treatment of type III prostatitis. Liaoning J Tradit Chin Med. 2014;41:1414–1416. [Google Scholar]
  • 19.Chu H. Benign prostatic hyperplasia treated by modified Danggui Beimu Kushen Wan: a report of 31 cases. J Pract Tradit Chin Med. 2002;18:14. [Google Scholar]
  • 20.Li Y., Gao X. Clinical experience from Professor Xixing Wang on Danggui Beimu Kushen Wan for the treatment of malignant tumor. Shanxi J Tradit Chin Med. 2011;27:4–6. [Google Scholar]
  • 21.China Association of Chinese Medicine . 5th ed. Hunan Electronic and Audio-Visual Publishing House; Changsha, China: 2015. Zhong Hua Yi Dian (Encyclopaedia of Traditional Chinese Medicine) [CD-ROM] [Google Scholar]
  • 22.May B.H., Zhang A., Lu Y., Lu C., Xue C.C. The systematic assessment of traditional evidence from the premodern Chinese medical literature: a text-mining approach. J Altern Complement Med. 2014;20:937–942. doi: 10.1089/acm.2013.0372. [DOI] [PubMed] [Google Scholar]
  • 23.Chang T.T. The origins and early cultures of the cereal grains and food legumes. In: Keightley D.N., editor. The Origins of Chinese Civilization. University of California Press; London, England: 1983. pp. 65–94. [Google Scholar]
  • 24.Xia J., Han L., Zhou X., Wei B. The effect of Zhejiang Fritillaria thunbergii against immunological CP/CPPS. Chin Arch Tradit Chin Med. 2011;28:1023–1025. [Google Scholar]
  • 25.Li H., Hung A., Yang A.W.H. A classic herbal formula Danggui Beimu Kushen Wan for chronic prostatitis: from traditional knowledge to scientific exploration. Evid Based Complement Altern Med. 2018;2018 doi: 10.1155/2018/1612948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wu D. Effects of Danggui Beimu Kushen decoction for the treatment of chronic bacterial prostatitis. Guide China Med. 2011;9:130–131. [Google Scholar]
  • 27.Guo B. A randomized controlled trial of modified Danggui Beimu Kushen Wan in 85 patients with chronic prostatitis. Forum Tradit Chin Med. 2008;23:7–8. [Google Scholar]
  • 28.Wu S. Clinical effects of chronic prostatitis with Chinese herbal medicine. Mod Chin Clin Med. 1994;1:38–40. [Google Scholar]
  • 29.Wang X. Chronic prostatitis treated by modified Danggui Beimu Kushen Wan: a report of 120 cases. West J Tradit Chin Med. 2007;20:39–40. [Google Scholar]
  • 30.Xi L., Yao T. 50 cases of benign prostatic hyperplasia with modified Danggui Beimu Kushen pills. J Changchun Univ Tradit Chin Med. 2007;23:58. [Google Scholar]
  • 31.State Administration of Traditional Chinese Medicine of the People’s Republic of China. Notice of the office of the state administration of TCM on issuing the clinical pathway of TCM and clinical diagnosis and treatment of TCM (2017 Edition) for 92 diseases such as stroke (cerebral infarction) 2017.
  • 32.He L. The effects of DANGGUIBEIMUKUSHEN decoction on IL-1β in the prostates of CBP rats. Chin Archives Tradit Chin Med. 2010;28:1524–1526. [Google Scholar]
  • 33.He L. Effects of DANGGUIBEIMUKUSHEN decoction on the whole blood viscosity of chronic bacterial prostatic rats. Zhejiang J Integr Tradit Chin West Med. 2013;23:12–13. [Google Scholar]
  • 34.He L., Fu Y., Ma Y., Cao F., Liu X. The effects of Danggui Beimu Kushen decoction on IL-2 and IL-8 in prostates in rats with chronic bacterial prostatitis. Chin J Tradit Med Sci Technol. 2010;17:505–506. [Google Scholar]
  • 35.He L., Fu Y., Ma Y., Cao F., Liu X. The effects of Danggui Beimu Kushen decoction on TNF-α in prostates in rats with chronic bacterial prostatitis. Chin J Exp Tradit Med Form. 2012;18:212–214. [Google Scholar]
  • 36.He L., Fu Y., Zhang L. Effects of Danggui Beimu Kushen decoction on ICAM-1 in the prostates of CBP rats. J Shanxi Coll Tradit Chin Med. 2012;13:20–21. [Google Scholar]
  • 37.He L., Fu Y., Zhang L. Impacts of Danggui Beimu Kushen decoction on prostatic WBC and SPL for the rats with chronic bacterial prostatitis. World J Integr Tradit West Med. 2012;7:1027–1028. [Google Scholar]
  • 38.Chen Y., Zhao D., Cai M., Wen D., Sun J. Antagonistic effect of Danggui Beimu Kushen Pill on prostatic hyperplasia in mice. Chin J Pharmacovigilance. 2010;7:4–6. [Google Scholar]
  • 39.Zhang Q. Guangxi Medical University; Nanning, China: 2011. Dangguibeimukushen Pill’s Effect on the Expression Change of PCNA, Bcl-2 and Bax in BPH Mice Model [MSD Thesis] [Google Scholar]
  • 40.Li H., Hung A., Li M., Yang A.W.H. Fritillariae Thunbergii Bulbus: Traditional uses, phytochemistry, pharmacodynamics, pharmacokinetics and toxicity. Int J Mol Sci. 2019;20:1667. doi: 10.3390/ijms20071667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wei W.-L., Zeng R., Gu C.-M., Qu Y., Huang L.-F. Angelica sinensis in China-A review of botanical profile, ethnopharmacology, phytochemistry and chemical analysis. J Ethnopharmacol. 2016;190:116–141. doi: 10.1016/j.jep.2016.05.023. [DOI] [PubMed] [Google Scholar]
  • 42.He X., Fang J., Huang L., Wang J., Huang X. Sophora flavescens Ait.: traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2015;172:10–29. doi: 10.1016/j.jep.2015.06.010. [DOI] [PubMed] [Google Scholar]
  • 43.Yang X., Zhao Y., Li G., Wang Z., Lv Y. Chemical composition and immuno-stimulating properties of polysaccharide biological response modifier isolated from Radix Angelica sinensis. Food Chem. 2008;106:269–276. [Google Scholar]
  • 44.Queiroz M.L., Torello C.O., Constantino A.T., Ramos A.L., Queiroz Jde S. Angelica sinensis modulates immunohematopoietic response and increases survival of mice infected with Listeria monocytogenes. J Med Food. 2010;13:1451–1459. doi: 10.1089/jmf.2009.0108. [DOI] [PubMed] [Google Scholar]
  • 45.Hong M.H., Lee J.Y., Jung H. Sophora flavescens Aiton inhibits the production of pro-inflammatory cytokines through inhibition of the NF κB/IκB signal pathway in human mast cell line (HMC-1) Toxicol In Vitro. 2009;23:251–258. doi: 10.1016/j.tiv.2008.12.002. [DOI] [PubMed] [Google Scholar]
  • 46.Jin J.H., Kim J.S., Kang S.S., Son K.H., Chang H.W., Kim H.P. Anti-inflammatory and anti-arthritic activity of total flavonoids of the roots of Sophora flavescens. J Ethnopharmacol. 2010;127:589–595. doi: 10.1016/j.jep.2009.12.020. [DOI] [PubMed] [Google Scholar]
  • 47.Kim H., Lee M.R., Lee G.S., An W.G., Cho S.I. Effect of Sophora flavescens Aiton extract on degranulation of mast cells and contact dermatitis induced by dinitrofluorobenzene in mice. J Ethnopharmacol. 2012;142:253–258. doi: 10.1016/j.jep.2012.04.053. [DOI] [PubMed] [Google Scholar]
  • 48.Lee J.H., Shin H., Kim Y.J., Paek S.H., Jin S., Ha U.H. Pseudomonas aeruginosa-induced IL-1beta production is inhibited by Sophora flavescens via the NF-kappaB/inflammasome pathways. J Microbiol. 2014;52:1044–1049. doi: 10.1007/s12275-014-4512-3. [DOI] [PubMed] [Google Scholar]
  • 49.Zhou M., Ma X., Ding G. Comparison and evaluation of antimuscarinic and anti-inflammatory effects of five Bulbus fritillariae species based on UPLC-Q/TOF integrated dual-luciferase reporter assay, PCA and ANN analysis. J Chromatogr B. 2017;1041-1042:60–69. doi: 10.1016/j.jchromb.2016.12.012. [DOI] [PubMed] [Google Scholar]
  • 50.Yang T., Jia M., Meng J., Wu H., Mei Q. Immunomodulatory activity of polysaccharide isolated from Angelica sinensis. Int J Biol Macromol. 2006;39:179–184. doi: 10.1016/j.ijbiomac.2006.02.013. [DOI] [PubMed] [Google Scholar]
  • 51.Zhang L. Jilin University; Changchun, China: 2014. Determination and Parmacokinetics Study on Ingredients In a Traditional Chinese Medicine Formula Danggui-Beimu-Kushen-Pill [MSD Thesis] [Google Scholar]
  • 52.Wang C.Y., Bai X.Y., Wang C.H. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med. 2014;42:543–559. doi: 10.1142/S0192415X14500359. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.docx (34.1KB, docx)
mmc2.docx (376.3KB, docx)
mmc3.docx (27.5KB, docx)

Data Availability Statement

The data used to support the findings of this study are included within the supplementary information files.

Articles from Integrative Medicine Research are provided here courtesy of Korea Institute of Oriental Medicine

RESOURCES